3 assets in Signet Ring Cell Carcinoma

Therapeutic assets addressing Signet Ring Cell Carcinoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE Signet Ring Cell Carcinoma	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Signet Ring Cell Carcinoma	University Hospital, Akershus	P2	CCC (53)
Oxaliplatin Signet Ring Cell Carcinoma	University Hospital, Akershus	P2	CCC (52)